These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1162 related articles for article (PubMed ID: 9058126)

  • 21. Significance of diminished factor XIII in Crohn's disease.
    Chamouard P; Grunebaum L; Wiesel ML; Sibilia J; Coumaros G; Wittersheim C; Baumann R; Cazenave JP
    Am J Gastroenterol; 1998 Apr; 93(4):610-4. PubMed ID: 9576457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.
    Nielsen OH; Brynskov J; Bendtzen K
    Dan Med Bull; 1993 Apr; 40(2):247-9. PubMed ID: 8495600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.
    Griga T; Voigt E; Gretzer B; Brasch F; May B
    Hepatogastroenterology; 1999; 46(26):920-3. PubMed ID: 10370639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.
    Maier W; Altwegg LA; Corti R; Gay S; Hersberger M; Maly FE; Sütsch G; Roffi M; Neidhart M; Eberli FR; Tanner FC; Gobbi S; von Eckardstein A; Lüscher TF
    Circulation; 2005 Mar; 111(11):1355-61. PubMed ID: 15753219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.
    Naftali T; Novick D; Gabay G; Rubinstein M; Novis B
    Isr Med Assoc J; 2007 Jul; 9(7):504-8. PubMed ID: 17710779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
    Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z
    Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune activation and nutritional status in adult Crohn's disease patients.
    Reimund JM; Arondel Y; Escalin G; Finck G; Baumann R; Duclos B
    Dig Liver Dis; 2005 Jun; 37(6):424-31. PubMed ID: 15893281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral butyrate for mildly to moderately active Crohn's disease.
    Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
    Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Polymorphism of the microsatellites and tumor necrosis factor genes in chronic inflammatory bowel diseases].
    Heresbach D; Ababou A; Bourienne A; Alizadeh M; Quelvennec E; Pagenault M; Dabadie A; Berre NH; Campion JP; Launois B; Gosselin M; Genetet B; Bretagne JF; Semana G
    Gastroenterol Clin Biol; 1997; 21(8-9):555-61. PubMed ID: 9587492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
    Valentini L; Wirth EK; Schweizer U; Hengstermann S; Schaper L; Koernicke T; Dietz E; Norman K; Buning C; Winklhofer-Roob BM; Lochs H; Ockenga J
    Nutrition; 2009 Feb; 25(2):172-81. PubMed ID: 18849144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].
    Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF
    Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission.
    Lindgren S; Florén CH; Lindhagen T; Starck M; Stewenius J; Nässberger L
    Eur J Gastroenterol Hepatol; 1995 Jun; 7(6):563-8. PubMed ID: 7552641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells.
    Ganapathi MK; Rzewnicki D; Samols D; Jiang SL; Kushner I
    J Immunol; 1991 Aug; 147(4):1261-5. PubMed ID: 1651357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.
    Katsanos KH; Tsatsoulis A; Christodoulou D; Challa A; Katsaraki A; Tsianos EV
    Growth Horm IGF Res; 2001 Dec; 11(6):364-7. PubMed ID: 11914023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.